55121-99-8

Basic information

• Product Name: 1-(4-AMINOBENZOYL)-4-METHYLPIPERAZINE
• Synonyms: 1-(4-AMINOBENZOYL)-4-METHYLPIPERAZINE;BUTTPARK 19\02-44;(4-Aminophenyl)(4-methylpiperazin-1-yl)methanone;4-[(4-Methyl-1-piperazinyl)carbonyl]aniline;NSC 27588;1-(4-Aminobenzoyl)-4-methyl piperidine;(4-aminophenyl)(4-methyl-1-piperazinyl)Methanone
• CAS NO: 55121-99-8
• Molecular Formula: C₁₂H₁₇N₃O
• Molecular Weight: 219.28
• Mol File: 55121-99-8.mol
• Article Data: 20

Chemical Properties

• Melting Point: 140℃
• Boiling Point: 407 °C at 760 mmHg
• Flash Point: 200 °C
• Appearance: /
• Density: 1.167
• Vapor Pressure: 7.78E-07mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 6.86±0.10(Predicted)
• CAS DataBase Reference: 1-(4-AMINOBENZOYL)-4-METHYLPIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-AMINOBENZOYL)-4-METHYLPIPERAZINE(55121-99-8)
• EPA Substance Registry System: 1-(4-AMINOBENZOYL)-4-METHYLPIPERAZINE(55121-99-8)

Safety Data

• Hazardous Substances Data: 55121-99-8(Hazardous Substances Data)

Usage

General Description

1-(4-aminobenzoyl)-4-methylpiperazine, also known as N-[4-[[4-(4-methyl-1-piperazinyl)phenyl]amino]phenyl]acetamide, is a chemical compound used in the pharmaceutical industry. It is a piperazine derivative that has shown potential as an antipsychotic and antidepressant agent in preclinical studies. The compound has been studied for its ability to modulate dopamine and serotonin receptors in the brain, and has displayed promising results in animal models of schizophrenia and depression. Additionally, it has been investigated for its potential as a treatment for other neuropsychiatric disorders, including anxiety and bipolar disorder. Further research is needed to fully understand the therapeutic potential and safety of 1-(4-aminobenzoyl)-4-methylpiperazine, but its unique chemical structure and pharmacological profile make it an interesting candidate for future drug development.

InChI:InChI=1/C12H17N3O/c1-14-6-8-15(9-7-14)12(16)10-2-4-11(13)5-3-10/h2-5H,6-9,13H2,1H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 122-04-3 4-nitro-benzoyl chloride 
• 21091-98-5 (4-methylpiperazin-1-yl)(4-nitrophenyl)methanone 
• 72141-41-4 (4-nitro-phenyl)-piperazin-1-yl-methanone 
• 50-00-0 formaldehyd 
• 72141-42-5 4-aminobenzoylpiperazine 
• 350684-49-0 4-(4-aminobenzoyl)piperazine-1-carboxylic acid tert-butyl ester 
• 509073-62-5 tert-butyl 4-(4-nitrobenzoyl)piperazine- 1-carboxylate 
• 150-13-0 4-amino-benzoic acid 
• 62-23-7 4-nitro-benzoic acid 
• 367-24-8 4-bromo-2-fluoroaniline 

Downstream Products

• 1180153-45-0 {4-[7-(3,5-Difluoro-4-morpholin-4-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
• 1197165-00-6 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazine-1-carbonyl)phenyl)urea 
• 1313481-17-2 (4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)(4-methylpiperazin-1-yl)methanone 
• 1332327-18-0 1-[4-(4-methyl-piperazine-1-carbonyl)-phenyl]-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-urea 
• 1374203-74-3 1-[4(6-fluoro-4-morpholin-4-yl-7-pyridin-3-yl-quinazolin-2-yl)-phenyl]-3-[4-(4-methyl-piperazine-1-carbonyl)-phenyl]-urea 
• 1374203-75-4 4-(3-{4-[8-(3-hydroxy-phenyl)-4-morpholin-4-yl-quinazolin-2-yl]-phenyl}-ureido)-N,N-dimethyl-benzamide 
• 1350767-53-1 4-(4-methylpiperazin-1-ylcarbonyl)phenylisocyanate 
• 1314996-60-5 7-Amino-8-ethyl-2-[4-(4-methylpiperazine-1-carbonyl)phenylamino]-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide 
• 1403817-50-4 (4-methylpiperazin-1-yl)(4-((5-(thiophen-3-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)phenyl)methanone 
• 1403817-36-6 (4-methylpiperazin-1-yl)(4-((5-(thiophen-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)phenyl)methanone 
• 1403817-33-3 5-(3-methoxyphenyl)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 
• 1197165-80-2 1-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-3-{4-[4-morpholin-4-yl-6-(oxetan-3-yloxy)-1,3,5-triazin-2-yl]phenyl}urea 
• 1197162-88-1 1-[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}urea 
• 1197165-77-7 1-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-3-(4-{4-morpholin-4-yl-6-[(3S)-tetrahydrofuran-3-yloxy]-1,3,5-triazin-2-yl}phenyl)urea 

Relevant articles and documents

PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF

The present invention discloses a pyrimidine compound, a preparation method thereof and a medical use thereof. Specifically, the present invention discloses a pyrimidine compound represented by formula (I), pharmaceutically acceptable salts thereof, a preparation method thereof, and a use thereof as a cyclin-dependent kinase 9 (CDK9) inhibitor, particularly for the treatment of cancer. The definition of each group in formula (I) is the same as that in the specification.

Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model

FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients. Recently, FLT3 inhibitors have been approved for AML therapy. Herein, a series of new compounds with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD. Compound 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line. Furthermore, the apoptosis and downregulation of P-STAT5 were also observed in tumor cells extracted from the MV4-11 cell xenografts model upon compound 46 treatment. Compound 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo. Compound 46 showed no toxicity to the viscera of mice and caused no decrease in body weight of mice. In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compound 46 was worthy of further development as potential drug candidate to treat AML.

Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors

Inhibition of LRRK2 kinase activity with small molecules has emerged as a potential novel therapeutic treatment for Parkinson's disease. Herein we disclose the discovery of a 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amine series as potent LRRK2 inhibitors id